With a growing number of patients using these medications for diabetes or to meet certain optimization goals before undergoing hip and knee reconstructive surgery, our aim was to establish evidence-based guidelines on when to discontinue these to enhance patient safety and surgical success. The study, Optimal Timing for Cessation of GLP-1 Agonist Before Elective Total Hip and Knee Arthroplasty, obtained data from the TriNetX Research Network, a multi-institutional national aggregated database, to identify patients who underwent TKA or THA from January 1, 2018 to January 1, 2023
Diagnostics (Basel) 2024;14:2829.ArticlePubMedPMC 7
Brello semaglutide pricing breakdown Pricing is one of Brello's strongest selling points, and it is worth examining in detail because the cost structure has a specific pattern that affects how you should think about the long-term commitment
A., Chan, C
The first injectable GLP-1 drug (semaglutide) was introduced in 2017 for treating diabetes under the tradename Ozempic
In January of this year, the FDA noted that it had "received adverse event reports after patients used compounded semaglutide" and that "patients should not use a compounded drug if an approved drug is available to treat a patient." In July, the agency followed up with a notice that it had "received reports of adverse events, some requiring hospitalization, that may be related to overdoses due to dosing errors associated with compounded semaglutide injectable products." And in August, Eli Lilly, the maker of Zepbound and Mounjaro, sent a series of cease-and-desist letters to providers urging them to stop prescribing compounded versions of those drugs